Capillary leak syndrome is characterized by the escape of blood plasma through capillary walls, from the blood circulatory system to surrounding tissues, muscle compartments, organs or body cavities.
EMA’s safety committee (PRAC) has recommended that people who have previously had capillary leak syndrome must not be vaccinated with COVID-19 Vaccine Janssen.
The adverse event was reported in 3 cases, after 3 people received Janssen COVID-19 vaccination. One of those affected had a history of capillary leak syndrome and two of them subsequently died.
The Committee also advised that capillary leak syndrome be listed as a new adverse effect of the vaccination in the product, along with a warning to raise awareness about the risks across healthcare professionals and patients.
Healthcare professionals should be aware of the signs and symptoms of capillary leak syndrome and of its risk of recurrence in people who have previously been diagnosed with the condition. Before the administration of vaccines and any type of medicine, consult your GP to highlight previous pathologies.
Another virus (of the adenovirus family) has been engineered to contain the gene for generating the S protein from SARS-CoV-2.
Read the official EMA announcement
Vaccines are safe, read WHO question and answers